Replies to post #1735 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ABBV/ENTA had a 54%* worldwide share of 4Q18 combined ABBV/GILD HCV sales:

#msg-146569117

[DewDiligence]

ENTA FY1Q19 results—GAAP EPS=$1.25:

https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-First-Quarter-and-Three-Months-Ended-December-31-2018/default.aspx

The cash balance at 12/31/18 was $357M.

[DewDiligence]

ABBV 1Q19 HCV sales=$815M—(-5% QoQ)—inline with 2019 guidance of $3.3B:

#msg-148427663